Table 1.
Patient and disease characteristics.
| n (% of total 161 patients) | |
|---|---|
| Age | |
| Median (range) | 62 (23–88) |
| Patients <65 years | 94 (58%) |
| Sex | |
| Male | 124 (77%) |
| Female | 37 (23%) |
| ECOG performance status | |
| 0–1 | 123 (76.4%) |
| ≥2 | 38 (23.6%) |
| Primary site | |
| Esophagus/gastroesophageal junction | 85 (53%) |
| Gastric | 76 (47%) |
| Grade | |
| Moderately differentiated | 51 (31.7%) |
| Poorly differentiated | 106 (65.8%) |
| Unknown | 4 (2.5%) |
| HER-2 status | |
| Positive | 18 (11.2%) |
| Negative | 139 (86.3%) |
| Unknown | 4 (2.5%) |
| MMR/MSI status | |
| MMR-deficient/MSI | 15 (9.3%) |
| MMR intact/MSS | 106 (65.8%) |
| Unknown | 40 (24.8%) |
| PD-L1 status | |
| PD-L1 positive | 45 (28%) |
| PD-L1 negative | 24 (14.9%) |
| Unknown | 92 (57.1%) |
| Number of prior regimens | |
| 0–2 | 112 (69.6%) |
| ≥3 (range 3–6) | 49 (30.4%) |
| Previous therapies | |
| Fluoropyrimidine | 137 (85%) |
| Platinum | 135 (84%) |
| Taxane | 96 (60%) |
| Ramucirumab | 65 (40%) |
| Irinotecan | 51 (32%) |
| Trastuzumab | 21 (13%) |
| Gemcitabine | 9 (6%) |
| Anthracycline | 5 (3%) |
| Other | 14 (9%) |
| Number of sites of disease at start of ICI | |
| 1–2 | 105 (65.2%) |
| ≥3 | 56 (34.8%) |
| Type of ICI | |
| Single-agent anti-PD-1/PD-L1 | 110 (68.3%) |
| Combination anti-CTLA-4 plus anti-PD-1/PD-L1 | 51 (31.7%) |
MMR, mismatch repair; MSI, microsatellite instability; MSS, microsatellite stable; PD-L1, programmed death-ligand-1; ICI, immune checkpoint inhibitors; anti-PD-1, anti-programmed cell death protein-1; anti-CTLA-4, anti-cytotoxic T-lymphocyte-associated protein-4.